By controlling insulin pathways and energy metabolism, hypoglycemic medications such as antidiabetic drugs (e.g., metformin), sodium-glucose cotransporter 2 (SGLT2) inhibitors, sodium-glucose cotransporter 1 (SGLT1) agonists, Dipeptidyl peptidase IV (DPP4) inhibitors, Glucagon-like peptide-1 receptor (GLP-1 RAs) agonists, liposomes, insulin, and Small interfering RNA (siRNA) have been shown to be effective in treating Alzheimer’s disease (Szablewski, 2017; Szablewski, 2021a; Wang et al., 2023). This evidence concerns the gene SLC5A1 and early-onset autosomal dominant Alzheimer disease.